Mayer M, Yedgar S, Joffe M, Shafrir E
Nephron. 1981;29(5-6):223-8. doi: 10.1159/000182376.
Induction of nephrosis in rats with aminonucleoside of puromycin (ANP) was followed by an increase in urinary protease activity, measured by the cleavage of 14C-globin, as well as in antiprotease activity measured by trypsin inhibition. The excretion of protease and protease inhibitor coincided with but did precede the onset of proteinuria when the ANP was injected subcutaneously for 5 days and lagged after proteinuria when the ANP was given as a single intravenous dose. Serum protease activity did not change throughout ANP treatment or later, whereas serum antiprotease capacity declined coincidently with proteinuria, most probably due to the loss in urine. Kidney proteolytic activity was markedly reduced in ANP nephrosis. Treatment of rats with proteolysis inhibitors, trasylol, episilon-aminocaproic acid, soybean trypsin inhibitor, or hexapron, together with ANP failed to prevent, delay or reduce the proteinuria. We believe that the urinary protease in ANP nephrosis does not originate from the circulation but from the release of kidney protease as a consequence of the glomerular lesion, and does not appear to be involved in its causation.
用嘌呤霉素氨基核苷(ANP)诱导大鼠发生肾病后,通过14C-珠蛋白裂解测定的尿蛋白酶活性增加,同时通过胰蛋白酶抑制测定的抗蛋白酶活性也增加。当皮下注射ANP 5天时,蛋白酶和蛋白酶抑制剂的排泄与蛋白尿的发生同时但并不先于蛋白尿出现,而当给予单次静脉剂量的ANP时,其排泄在蛋白尿之后延迟。在整个ANP治疗期间及之后,血清蛋白酶活性没有变化,而血清抗蛋白酶能力与蛋白尿同时下降,很可能是由于尿液中的丢失。ANP肾病时肾脏的蛋白水解活性明显降低。用蛋白水解抑制剂(抑肽酶、ε-氨基己酸、大豆胰蛋白酶抑制剂或六亚甲基二乙酰胺)与ANP一起治疗大鼠,未能预防、延缓或减少蛋白尿。我们认为,ANP肾病中的尿蛋白酶并非源自循环系统,而是由于肾小球病变导致肾脏蛋白酶释放所致,并且似乎不参与其病因形成。